Pacira BioSciences heads into its July 31 earnings report with a notable gap opening between a still-heavy short position and a stock that has quietly put together its best month in some time.
The short interest story is genuinely interesting here — but it is moving in the bears' favour less than it was. At 14.8% of the free float, PCRX carries one of the heavier short loads in specialty pharma. Yet that number has fallen roughly 19% over the past month, retreating from a peak near 20% in late May. The week-on-week change was also slightly down, at -2.9%, even as the stock gained 7.9% to close at $25.37. Borrow conditions offer no sign of stress building on the short side: availability is generous at around 292% of short interest, well above the 52-week trough of 216%, meaning there is no shortage of shares to borrow for anyone who wants to press a bearish bet. Cost to borrow is near flat at 0.54% — effectively free money to hold a short. The combination of falling short interest and loose borrow conditions reads less like a squeeze building and more like gradual short-side capitulation.
Options traders are leaning call-heavy relative to the recent past. The put/call ratio is 0.32, modestly below its 20-day average of 0.34 and more than half a standard deviation lighter on put demand than normal. That is not an extreme reading — it sits well within the year's range of 0.16 to 0.96 — but the direction of travel confirms that speculative money is positioned for more upside rather than hedging hard into the print. The ORTEX short score of 72.9 is elevated in absolute terms, ranking in roughly the 89th percentile of the universe, yet it has been broadly stable for two weeks, suggesting the short thesis is entrenched rather than escalating.
The Street picture is split, though tilted constructive. HC Wainwright reiterated its Buy and $38 target on July 1 — the most recent action and still the highest target in the coverage universe. Needham has a $32 Buy. RBC sits more cautiously at Sector Perform with a $24 target, sitting almost exactly at where the stock traded through most of May and June. The mean target of roughly $30 implies about 17% upside from current levels. Bulls point to steady EXPAREL volume growth, clarity from a generic competitor settlement, and the early-stage pipeline around PCRX-201 as reasons to own the name. Bears lean on vial mix headwinds, pricing pressure from GPO partnerships, and a ZILRETTA ramp that has underperformed initial projections. On valuation, the PE of 6.9 and EV/EBITDA of 5.1 are low for specialty pharma — and the 12-month forward EPS growth factor scores in the 97th percentile of the universe, a combination that underpins the bull case on paper.
Insider activity over the past 90 days is worth a note, though it reads mostly as routine. The net position across all insiders is a combined sale of roughly $1.45 million in shares, driven by the CFO offloading around $628,000 across four consecutive days in late April, and the Chief Administration Officer selling twice in early June. These were plan-driven-sized disposals rather than large strategic exits, and none carry outsized significance scores. The pattern is worth flagging as a mild negative signal, but it is not the kind of concentrated selling that historically precedes major guidance resets.
Earnings history adds a note of caution. The last four results-day reactions were two small gains and two declines of roughly 2.8% and 3.1%, with five-day follow-through significantly worse on the negative prints — the May 1 report saw the stock down 9.2% over the subsequent week. With the next event scheduled for July 31, the setup worth watching is whether the short-cover rally of the past month holds into the print, or whether any disappointment on EXPAREL pricing or ZILRETTA volumes revives the selling pressure that dominated the first half of May.
See the live data behind this article on ORTEX.
Open PCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
